Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2671 to 2685 of 9024 results

  1. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Severe mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  3. Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date:  05 August 2026

    NICE guideline
    In development

  5. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date:  17 December 2027

    NICE guideline
    In development

  6. Percutaneous intraductal radiofrequency ablation for malignant biliary obstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 June 2026.

    Technology appraisal guidance
    In consultation

  9. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 10 June 2026.

    In consultation

  10. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 28 May 2026.

    Technology appraisal guidance
    In consultation

  11. Seminal Vesicle Lavage

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

    Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    6 October 2015

  13. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 September 2013

  14. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Evidence summary
    Published
    5 January 2021

  15. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021